• FDA grants priority review to Lynparza regimen for advanced prostate cancer

    1 month ago - By Healio

    The FDA granted priority review to olaparib as part of combination therapy treatment of metastatic castration-resistant prostate cancer.
    Olaparib is a poly polymerase inhibitor approved in the United States for multiple cancer indications.
    The priority review designation - which applies to use of the agent in combination with abiraterone acetate and prednisone or prednisolone - is based on results of the randomized phase 3 PROpel study.
    The study included 796 men undergoing first-line treatment for metastatic castration-resistant
    Read more ...